Literature DB >> 8385703

An ELISA using recombinant proteins for the detection of neutralizing antibodies against human cytomegalovirus.

B Kropff1, M P Landini, M Mach.   

Abstract

Two prokaryotically expressed fusion proteins encompassing amino acids 484-650 (AD-1) and 27-100 (AD-2) of glycoprotein gp58/116 of human cytomegalovirus (HCMV) were purified from E. coli lysates and used in ELISA to determine antibody levels in human sera. The specificity of the test was established by comparison of 116 randomly selected sera with commercially available HCMV-ELISA tests. The recombinant polypeptides were then used for the analysis of antibody titers in 112 human sera and were compared to the capacity to neutralize HCMV. A strong correlation between the neutralization titer and antibody levels against AD-1 and a weaker correlation for AD-2 was observed. Of 29 sera with a high neutralization titer (> 1:128), 96% and 62% were positive for AD-1 and AD-2, respectively, while 44% and 19% were positive in sera with low neutralization titer (< 1:8). Serum pools prepared from human sera selected on the basis of recognition of the recombinant antigens had a 10-fold higher neutralization capacity than pools prepared from sera with a high titer in commercially available HCMV tests. A synchronous increase in neutralization capacity and titer against recombinant antigens was observed in transplant patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8385703     DOI: 10.1002/jmv.1890390303

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  10 in total

1.  Enzyme-linked immunosorbent assay method for detection of cytomegalovirus strain-specific antibody responses.

Authors:  Zdenek Novak; Shannon A Ross; Raj Kumar Patro; Sunil Kumar Pati; Meera K Reddy; Misty Purser; William J Britt; Suresh B Boppana
Journal:  Clin Vaccine Immunol       Date:  2008-11-26

2.  Cytomegalovirus glycoprotein B-specific antibody analysis using electrochemiluminescence detection-based techniques.

Authors:  M Ohlin; M Silvestri; V A Sundqvist; C A Borrebaeck
Journal:  Clin Diagn Lab Immunol       Date:  1997-01

Review 3.  Role of antibodies in confining cytomegalovirus after reactivation from latency: three decades' résumé.

Authors:  Astrid Krmpotić; Jürgen Podlech; Matthias J Reddehase; William J Britt; Stipan Jonjić
Journal:  Med Microbiol Immunol       Date:  2019-03-28       Impact factor: 3.402

4.  Antigenic domain 1 is required for oligomerization of human cytomegalovirus glycoprotein B.

Authors:  William J Britt; Michael A Jarvis; Derek D Drummond; Michael Mach
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

5.  Humoral immune response against human cytomegalovirus (HCMV)-specific proteins after HCMV infection in lung transplantation as detected with recombinant and naturally occurring proteins.

Authors:  J van Zanten; M C Harmsen; M van der Giessen; W van der Bij; J Prop; L de Leij; T H The
Journal:  Clin Diagn Lab Immunol       Date:  1995-03

6.  Recent Approaches and Strategies in the Generation of Anti-human Cytomegalovirus Vaccines.

Authors:  Suresh B Boppana; William J Britt
Journal:  Methods Mol Biol       Date:  2021

7.  A derivative of platelet-derived growth factor receptor alpha binds to the trimer of human cytomegalovirus and inhibits entry into fibroblasts and endothelial cells.

Authors:  Cora Stegmann; Daniel Hochdorfer; Diana Lieber; Narmadha Subramanian; Dagmar Stöhr; Kerstin Laib Sampaio; Christian Sinzger
Journal:  PLoS Pathog       Date:  2017-04-12       Impact factor: 6.823

8.  Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine With MF59: Anti-AD2 Levels Correlate With Protection From Viremia.

Authors:  Ilona Baraniak; Barbara Kropff; Gary R McLean; Sylvie Pichon; Fabienne Piras-Douce; Richard S B Milne; Colette Smith; Michael Mach; Paul D Griffiths; Matthew B Reeves
Journal:  J Infect Dis       Date:  2018-05-25       Impact factor: 5.226

9.  Highly quantitative serological detection of anti-cytomegalovirus (CMV) antibodies.

Authors:  Peter D Burbelo; Alexandra T Issa; Kathryn H Ching; Maurice Exner; W Lawrence Drew; Harvey J Alter; Michael J Iadarola
Journal:  Virol J       Date:  2009-05-01       Impact factor: 4.099

10.  Generation of potent neutralizing human monoclonal antibodies against cytomegalovirus infection from immune B cells.

Authors:  Ada Funaro; Giorgio Gribaudo; Anna Luganini; Erika Ortolan; Nicola Lo Buono; Elisa Vicenzi; Luca Cassetta; Santo Landolfo; Richard Buick; Luca Falciola; Marianne Murphy; Gianni Garotta; Fabio Malavasi
Journal:  BMC Biotechnol       Date:  2008-11-12       Impact factor: 2.563

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.